Skip to main content
Fig. 2 | International Journal of Retina and Vitreous

Fig. 2

From: Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

Fig. 2

Time from redemption of first prescription of once-weekly semaglutide (Ozempic®) to first event of nonarteritic anterior ischemic optic neuropathy (NAION) in the 67 persons with type 2 diabetes patients, who were exposed to semaglutide and developed at least one event of NAION in 2018–2024. Box and whisker plot includes median time, interquartile range and range

Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us